Simplex Trading’s Y-mAbs Therapeutics YMAB Stock Holding History

Simplex Trading’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-600	Closed	-$2K	–	10244
2025 Q2	$2K	Buy	+600	New	+$2.7K	﹤0.01%	8233
2025 Q1	–	Sell	-200	Closed	-$1K	–	9871
2024 Q4	$1K	Buy	+200	New	+$2.44K	﹤0.01%	8344
2024 Q2	–	Sell	-1,500	Closed	-$24K	–	9995
2024 Q1	$24K	Buy	+1,500	New	+$20.2K	﹤0.01%	6966
2022 Q3	–	Sell	-400	Closed	-$6K	–	11034
2022 Q2	$6K	Buy	+400	New	+$4.67K	﹤0.01%	8762
2021 Q2	–	Sell	-4	Closed	-$12K	–	10818
2021 Q1	$12K	Buy	+4	New	+$164	﹤0.01%	7816

Other funds holding YMAB

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Simplex Trading's YMAB Position: Q2 2025 in Review

Simplex Trading sold out of Y-mAbs Therapeutics (YMAB) in Q2 2025, closing a stake of 437 shares — an estimated $1.96K sold.

Simplex Trading first reported a position in YMAB in Q4 2020 and held it in 10 quarters. The position peaked at $27K in Q3 2022. 97 funds tracked by Wall St. Rank hold YMAB as of Q2 2025.

Simplex Trading reported no remaining Y-mAbs Therapeutics position as of Q2 2025 after selling out during the quarter.
Simplex Trading sold 437 Y-mAbs Therapeutics shares in Q2 2025, an estimated $1.96K.
Simplex Trading first reported a position in Y-mAbs Therapeutics in Q4 2020 and held it in 10 quarters.
Simplex Trading's Y-mAbs Therapeutics position peaked at $27K in Q3 2022.
97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2025.

Based on Simplex Trading's 13F filing for Q2 2025, filed 5 Aug 2025.